Search

Displaying results 2501 - 2510 of 10000 in total
  1. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms. … Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that

  2. Drug

    Polythiazide

    go.drugbank.com/drugs/DB01324
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)

  3. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

    Synonyms: 4'-N-benzoylstaurosporine
  4. Drug

    Potassium perchlorate

    go.drugbank.com/drugs/DB09418
    ApprovedWithdrawn

    Potassium is most commonly used in flares and automobile airbags [A32609]. … Potassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates.

  5. Drug

    Benzonatate

    go.drugbank.com/drugs/DB00868
    Approved

    Benzonatate is an oral antitussive drug used in the relief and suppression of cough in patients older than ten years of age. … Benzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.

    Synonyms: nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate
  6. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an

  7. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    on anti-PD-1 therapy. … on a PD-1-blocking antibody-based regimen.

  8. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.

    Products: Copaxone 20 mg/ml Injektionslösung in einer Fertigspritze, Copaxone 40 mg/ml Injektionslösung in einer Fertigspritze
  9. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. … Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing

  10. Drug

    Droxicam

    go.drugbank.com/drugs/DB09215
    ApprovedWithdrawn

    Droxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of [DB00554]. … It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.